© Discover Echo Inc.

Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.

picture: ©thermo scientific

The Thermo Scientific HyPerforma GXCore Bioprocess Controller is an innovative, compact, cost-effective, open-architecture controller built for research and process development applications.

© RheinCell Therapeutics GmbH

Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.

Face2Gene applications. © FDNA

In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.

At the beginning of June, Sidonie Fabre strengthens Advent France Biotechnology (AFB) as new Chief Financial Officer.

BBB © NIH, Kristin Johnson/Vascular Biology Program, Boston Children's Hospital

NeuVasQ Biotechnologies has raised €20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.

© Coriolis Pharma

Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.

picture: ©CPC

Which connection method do most industry professionals prefer: tube welding or aseptic connectors? A recent survey revealed their preferences are almost equally split between the two. But that doesn’t mean one method might not be better for your needs.

On 13 April 2021, Evotec SE launched beLAB2122 in collaboration with Bristol-Myers Squibb company and five top-tier academic institutions. Mediated and supported by BioRN Life Science Cluster Rhine-Neckar, this $20 million BRIDGE brings together leading academic institutions in Southwestern Germany with the goal of efficiently advancing novel drug discovery projects.

Picture: Tigermed

The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies?